Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 May;46(5):1350.
doi: 10.1038/s41440-023-01204-2. Epub 2023 Feb 21.

Aldosterone breakthrough from a pharmacological perspective

José Alfie  1   2
Affiliations
Comment

Aldosterone breakthrough from a pharmacological perspective

José Alfie. Hypertens Res. 2023 May.
No abstract available

Keywords: Aldosterone breakthrough; Aldosterone to renin ratio; RAS blockade.

PubMed Disclaimer

Comment in

Comment on

References

    1. Mogi M. Aldosterone breakthrough from a pharmacological perspective. Hypertens Res. 2022;45:967–975. https://doi.org/10.1038/s41440-022-00913-4 - DOI - PubMed
    1. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91:457–65. https://doi.org/10.1677/joe.0.0910457 - DOI - PubMed
    1. Horita Y, Taura K, Taguchi T, Furusu A, Kohno S Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology (Carlton). 2006;11:462-6. https://doi.org/10.1111/j.1440-1797.2006.00665.x .
    1. Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens. 2003;16:781–8. https://doi.org/10.1016/s0895-7061(03)00913-0 . - DOI - PubMed
    1. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6:464–475. https://doi.org/10.1016/S2213-8587(18)30071-8 . - DOI - PubMed - PMC

LinkOut - more resources